Profound Medical Corp.
For the period ended Oct 28, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 28, 2026 · Filed Nov 3, 2026
Use the contents to explore the available documents and sections.
PROF$7.21+4.8%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Note
Note
1 Profound is working with the U.S. Food and Drug Administration ("FDA") to obtain 510(k) clearance for the use of TULSA-PRO with the MAGNETOM Free.Max MR scanner. TULSA-PRO is already FDA-cleared for use with multiple compatible 1.5T and 3T MRI systems, and has been CE marked for use with MAGNETOM Free.Max in Europe.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.